Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells.

Reitman ZJ, Paolella BR, Bergthold G, Pelton K, Becker S, Jones R, Sinai CE, Malkin H, Huang Y, Grimmet L, Herbert ZT, Sun Y, Weatherbee JL, Alberta JA, Daley JF, Rozenblatt-Rosen O, Condurat AL, Qian K, Khadka P, Segal RA, Haas-Kogan D, Filbin MG, Suva ML, Regev A, Stiles CD, Kieran MW, Goumnerova L, Ligon KL, Shalek AK, Bandopadhayay P, Beroukhim R.

Nat Commun. 2019 Aug 19;10(1):3731. doi: 10.1038/s41467-019-11493-2.

2.

New Directions in the Treatment of Glioblastoma.

Reitman ZJ, Winkler F, Elia AEH.

Semin Neurol. 2018 Feb;38(1):50-61. doi: 10.1055/s-0038-1623534. Epub 2018 Mar 16. Review.

PMID:
29548052
3.

Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation.

Cagney DN, Martin AM, Catalano PJ, Reitman ZJ, Mezochow GA, Lee EQ, Wen PY, Weiss SE, Brown PD, Ahluwalia MS, Arvold ND, Tanguturi SK, Haas-Kogan DA, Alexander BM, Redig AJ, Aizer AA.

Radiother Oncol. 2018 Mar;126(3):511-518. doi: 10.1016/j.radonc.2018.01.005. Epub 2018 Feb 3.

PMID:
29398153
4.

Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.

Chitneni SK, Reitman ZJ, Spicehandler R, Gooden DM, Yan H, Zalutsky MR.

Bioorg Med Chem Lett. 2018 Feb 15;28(4):694-699. doi: 10.1016/j.bmcl.2018.01.015. Epub 2018 Jan 12.

5.

The genome-wide mutational landscape of pituitary adenomas.

Song ZJ, Reitman ZJ, Ma ZY, Chen JH, Zhang QL, Shou XF, Huang CX, Wang YF, Li SQ, Mao Y, Zhou LF, Lian BF, Yan H, Shi YY, Zhao Y.

Cell Res. 2016 Nov;26(11):1255-1259. doi: 10.1038/cr.2016.114. Epub 2016 Sep 27. No abstract available.

6.

Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.

Chitneni SK, Reitman ZJ, Gooden DM, Yan H, Zalutsky MR.

Eur J Med Chem. 2016 Aug 25;119:218-30. doi: 10.1016/j.ejmech.2016.04.066. Epub 2016 Apr 28.

7.

Smaller protein, larger therapeutic potential: PPM1D as a new therapeutic target in brainstem glioma.

Reitman ZJ.

Pharmacogenomics. 2014 Sep;15(13):1639-41. doi: 10.2217/pgs.14.123. No abstract available.

8.

Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.

Reitman ZJ, Sinenko SA, Spana EP, Yan H.

Blood. 2015 Jan 8;125(2):336-45. doi: 10.1182/blood-2014-05-577940. Epub 2014 Nov 14.

9.

Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.

Reitman ZJ, Duncan CG, Poteet E, Winters A, Yan LJ, Gooden DM, Spasojevic I, Boros LG, Yang SH, Yan H.

J Biol Chem. 2014 Aug 22;289(34):23318-28. doi: 10.1074/jbc.M114.575183. Epub 2014 Jul 1.

10.

Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.

Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, Yang S, Jones S, Wang S, Zhou W, Zhu H, Killela PJ, Zhang J, Wu Z, Li G, Hao S, Wang Y, Webb JB, Friedman HS, Friedman AH, McLendon RE, He Y, Reitman ZJ, Bigner DD, Yan H.

Nat Genet. 2014 Jul;46(7):726-30. doi: 10.1038/ng.2995. Epub 2014 Jun 1.

11.

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.

Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon JE 2nd, Yan H, Bigner DD.

Oncotarget. 2014 Mar 30;5(6):1515-25.

12.

Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors.

Reitman ZJ, Pirozzi CJ, Yan H.

Acta Neuropathol. 2013 Dec;126(6):789-92. doi: 10.1007/s00401-013-1207-5. No abstract available.

13.

The genetic landscape of anaplastic astrocytoma.

Killela PJ, Pirozzi CJ, Reitman ZJ, Jones S, Rasheed BA, Lipp E, Friedman H, Friedman AH, He Y, McLendon RE, Bigner DD, Yan H.

Oncotarget. 2014 Mar 30;5(6):1452-7.

14.

Relationship Between Time of First Publication and Subsequent Publication Success Among Non-PhD Physician-Scientists.

Riggs KR, Reitman ZJ, Mielenz TJ, Goodman PC.

J Grad Med Educ. 2012 Jun;4(2):196-201. doi: 10.4300/JGME-D-11-00068.1.

15.

Releasing the block: setting differentiation free with mutant IDH inhibitors.

Pirozzi CJ, Reitman ZJ, Yan H.

Cancer Cell. 2013 May 13;23(5):570-2. doi: 10.1016/j.ccr.2013.04.024.

16.

Exomic sequencing of four rare central nervous system tumor types.

Bettegowda C, Agrawal N, Jiao Y, Wang Y, Wood LD, Rodriguez FJ, Hruban RH, Gallia GL, Binder ZA, Riggins CJ, Salmasi V, Riggins GJ, Reitman ZJ, Rasheed A, Keir S, Shinjo S, Marie S, McLendon R, Jallo G, Vogelstein B, Bigner D, Yan H, Kinzler KW, Papadopoulos N.

Oncotarget. 2013 Apr;4(4):572-83.

17.

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IeM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6. doi: 10.1073/pnas.1303607110. Epub 2013 Mar 25.

18.

Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.

Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez GY, He Y, McLendon RE, Bigner DD, Yan H.

Cancer Res. 2013 Jan 15;73(2):496-501. doi: 10.1158/0008-5472.CAN-12-2852. Epub 2012 Nov 30.

19.

Enzyme redesign guided by cancer-derived IDH1 mutations.

Reitman ZJ, Choi BD, Spasojevic I, Bigner DD, Sampson JH, Yan H.

Nat Chem Biol. 2012 Nov;8(11):887-9. doi: 10.1038/nchembio.1065. Epub 2012 Sep 23.

20.

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.

Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H.

Oncotarget. 2012 Jul;3(7):709-22.

21.

2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.

Jin G, Reitman ZJ, Spasojevic I, Batinic-Haberle I, Yang J, Schmidt-Kittler O, Bigner DD, Yan H.

PLoS One. 2011 Feb 4;6(2):e16812. doi: 10.1371/journal.pone.0016812.

22.

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.

Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H.

Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3270-5. doi: 10.1073/pnas.1019393108. Epub 2011 Feb 2.

23.

IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain.

Lopez GY, Reitman ZJ, Solomon D, Waldman T, Bigner DD, McLendon RE, Rosenberg SA, Samuels Y, Yan H.

Biochem Biophys Res Commun. 2010 Jul 30;398(3):585-7. doi: 10.1016/j.bbrc.2010.06.125. Epub 2010 Jul 13.

24.

Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.

Reitman ZJ, Yan H.

J Natl Cancer Inst. 2010 Jul 7;102(13):932-41. doi: 10.1093/jnci/djq187. Epub 2010 May 31. Review.

25.

IDH1 and IDH2: not your typical oncogenes.

Reitman ZJ, Parsons DW, Yan H.

Cancer Cell. 2010 Mar 16;17(3):215-6. doi: 10.1016/j.ccr.2010.02.024.

26.

IDH1 and IDH2 hotspot mutations are not found in canine glioma.

Reitman ZJ, Olby NJ, Mariani CL, Thomas R, Breen M, Bigner DD, McLendon RE, Yan H.

Int J Cancer. 2010 Jul 1;127(1):245-6. doi: 10.1002/ijc.25017. No abstract available.

27.

Supplemental Content

Loading ...
Support Center